Regulation of radiosensitivity by HDAC inhibitor trichostatin A in the human cervical carcinoma cell line Hela

Histone deacetylase (HDAC) inhibitors play an important role in inducing growth arrest, differentiation, and/or apoptosis in cancer cells. Given their ability to disrupt critical biological processes in cancer cells, these agents are emerging as potential therapeutics for cancer. Recently, it has been identified that HDAC inhibitors can also efficiently enhance the radiation sensitivity of cells, both in vitro and in vivo. In this study, we investigated whether the potent HDAC inhibitor, Trichostatin A, modulates the radiation sensitivity of the human cervical carcinoma cell line Hela under hypoxic conditions. We concluded that TSA could significantly inhibit the proliferation of Hela cells in a dose-and time-dependent manner under normoxic and hypoxic conditions. Hypoxia resulted in the cervical carcinoma Hela cells resistant to TSA. The findings from clonogenic survival assays indicate that incubation with TSA for 24 hours prior to irradiation enhances the radiation sensitivity of Hela cells under hypoxic conditions. More generally, we found Hela cells under hypoxic conditions treated with TSA could significantly down-regulate the expressions of HIF-1 alpha and VEGF proteins. Taken together, our results demonstrated that TSA acts as a powerful radiosensitizer in Hela cells under hypoxic conditions probably by down-regulated expression of HIF-1 alpha and VEGF proteins.

Tumor cell; Hypoxia; Radiosensitivity

[1] Harrison L., Blackwell K.: “Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy”. Oncologist, 2004, 9 (suppl. 5), 31.

[2] Tredan O., Galmarini C.M., Patel K., Tannock I.F.: “Drug resistance and the solid tumor microenvironment”. J. Natl. Cancer Inst., 2007, 99, 1441.

[3] Lara P.C., Lloret M., Clavo B., Apolenario R.M., Henriquez-Hermández L.A., Bordón N. et al.: “Severe hypoxia induces chemoresistance in clinical cervical tumors through MVP over-expression”. Radiat. Oncol., 2009, 4, 29.

[4] Sasabe E., Zhou X., Li D., Oku N., Yamamoto T., Osaki T.: “The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells”. Int. J. Cancer, 2007, 120, 268.

[5] Rohwer N., Dame C., Haugstetter A., Wiedenmann B., Detjen K., Schmitt C.A. Cramer T.: “Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB”. PLOS ONE, 2010, 5, e12038.

[6] Wachsberger P. BR, Dicker A.P.: “Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction”. Clin. Cancer Res., 2003, 9, 1957.

[7] Lartigau E: “Radiation sensitizing agents for hypoxic cells: past, present and future”. Cancer Radiother., 1998, 2, 775.

[8] Bischoff P., Altmeyer A., Dumont F.: “Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers”. Expert. Opin. Ther. Pat., 2009, 19, 643.

[9] MacDonald V.E., Howe L.J.: “Histone acetylation: where to go and how to get there”. Epigenetics, 2009, 4, 139.

[10] Zhang D., Liu C.T., Yu X.D., Liu Y.: “Effects of trichostatin A on human lung cancer cell strains A549”. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2010, 32, 167.

[11] Kim H.R., Kim E.J., Yang S.H., Jeong E.T., Park C., Lee J.H. et al.: “Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway”. Exp. Mol. Med., 2006, 38, 616.

[12] Piacentini P., Donadelli M., Costanzo C., Moore P.S., Palmieri M., Scarpa A.: “Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation”. Virchows Arch., 2006, 448, 797.

[13] Zupkovitz G., Grausenburger R., Brunmeir R., Senese S., Tischler J., Jurkin J. et al.: “The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation”. Mol. Cell. Biol., 2010, 30, 1171.

[14] Tsuji N., Kobayashi M., Nagashima K., Wakisaka Y., Koizumi K.: “A new antifungal antibiotic, trichostatin”. J. Antibiot. (Tokyo), 1976, 29, 1.

[15] Marks P.A., Richon V.M., Breslow R., Rifkind R.A.: “Histone deacetylase inhibitors as new cancer drugs”. Curr. Opin. Oncol., 2001, 13, 477.

[16] Jang E.R., Lim S.J., Lee E.S., Jeong G., Kim T.Y., Bang Y.J., Lee J.S.: “The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha negative breast cancer cells to tamoxifen”. Oncogene, 2004, 23, 1724.

[17] Karagiannis T.C., Harikrishnan K.N., El-Osta A.: “The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X”. Cancer Biol. Ther., 2005, 4, 787.

[18] Yang Q.C., Zeng B.F., Shi Z.M., Dong Y., Jiang Z.M., Huang J. et al.: “Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma”. J. Exp. Clin. Cancer Res., 2006, 25, 593.

[19] Zhang F., Zhang T., Teng Z.H., Zhang R., Wang J.B., Mei Q.B.: “Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells”. Cancer Biol. Ther., 2009, 8, 823.

[20] Soslow R.A., Dannenberg A.J., Rush D., Weener B.M., Khan K.N., Masferrer J., Koki A.T.: “COX-2 is expressed in human pulmonary, colonic, and mammary tumors”. Cancer, 2000, 89, 2637.

[21] Mai A., Massa S., Rotili D., Cerbara I., Valente S., Pezzi R. et al.: “Histone deacetylation in epigenetics: an attractive target for anticancer therapy”. Med. Res. Rev., 2005, 25, 261.

[22] Shabbeer S., Carducci M.A.: “Focus on deacetylation for therapeutic benefit”. IDrugs, 2005, 8, 144.

[23] Zhang Y., Jung M., Dritschilo A., Jung M.: “Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors”. Radiat. Res., 2004, 161, 667.

[24] Arundel C.M., Glicksman A.S., Leith J.T.: “Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB)”. Radiat. Res., 1985, 104, 443.

[25] Camphausen K., Burgan W., Cerra M., Oswald K.A., Prepel J., Lee M.J., Tofilon P.J.: “Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275”. Cancer Res., 2004, 64, 316.

[26] Camphausen K., Cerna D., Scott T., Sproull M, Burgan W.E., Cerra M.A. et al.: “Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid”. Int. J. Cancer, 2005, 114, 380.

[27] Camphausen K., Tofilon P.J.: “Inhibition of histone deacetylation: a strategy for tumor radiosensitization”. J. Clin. Oncol., 2007, 25, 4051.

[28] Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M.: “Modulation of radiation response by histone deacetylase inhibition”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 223.

[29] Chung Y.L., Wang A.J., Yao L.F.: “Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy”. Mol. Cancer Ther., 2004, 3, 317.

[30] Paoluzzi L., Figg W.D.: “Histone deacetylase inhibitors are potent radiation protectants”. Cancer Biol. Ther., 2004, 3, 612.

[31] Zhang F., Zhang T., Teng Z.H., Zhang R., Wang J.B., Mei Q.B.: “Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells”. Cancer Biol. Ther., 2009, 8, 823.

[32] Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W. et al.: “Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes”. Nat. Med., 2001, 7, 437.

[33] Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N. et al.: “Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling”. Oncogene, 2002, 21, 427.